Citadel Advisors
PRLD icon

Citadel Advisors’s Prelude Therapeutics PRLD Stock Holding History

Citadel Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$167K Buy
+31,300
New +$136K ﹤0.01% 12253
2024
Q4 		– Sell
-300
Closed -$621 – 15183
2024
Q3 		$621 Buy
300
+200
+200% +$926 ﹤0.01% 13984
2024
Q2 		$381 Buy
+100
New +$407 ﹤0.01% 14006
2024
Q1 		– Sell
-1,000
Closed -$4.27K – 15279
2023
Q4 		$4.27K Sell
1,000
-200
-17% -$609 ﹤0.01% 13522
2023
Q3 		$3.71K Hold
1,200
– – ﹤0.01% 13558
2023
Q2 		$5.4K Buy
+1,200
New +$7.17K ﹤0.01% 13506

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Citadel Advisors's PRLD Position: Q2 2026 in Review

Citadel Advisors reduced its Prelude Therapeutics (PRLD) stake by 82% in Q2 2026, selling an estimated $443K and leaving 22,554 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #12533.

Citadel Advisors first reported a position in PRLD in Q3 2020 and has held it in 19 quarters since. The position peaked at $3.34M in Q3 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Citadel Advisors held 22,554 shares of Prelude Therapeutics worth $120K as of Q2 2026.
  • Citadel Advisors sold 101,824 Prelude Therapeutics shares in Q2 2026, an estimated $443K.
  • Prelude Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12533 holding.
  • Citadel Advisors first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 19 quarters since.
  • Citadel Advisors's Prelude Therapeutics position peaked at $3.34M in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.